Australia puts forward A$17 million in funding for TB research

26 March 2024
lab_biotech_research_vaccine_big

Not-for-profit research partnership TB Alliance has won a A$17 million (US$11.1 million) grant from the Australian government to continue its work combating tuberculosis.

The funding will contribute towards the completion of a Phase II trial, NC-009, which is taking place in multiple countries around the world and which began enrollment late last year.

The study is testing the safety and efficacy of a combination of TBAJ-876, pretomanid and linezolid, for its potential to shorten and improve treatment for both drug-sensitive and drug-resistant tuberculosis.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical